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ABSTRACT 
Irritable bowel syndrome (IBS) is a troubling disease experienced worldwide. The presentation 
of symptoms varies from patient to patient, and current prescription treatments can be inadequate 
in resolving symptoms. This article explores the available scientific literature supporting the use 
of melatonin in alleviating IBS symptoms. 
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INTRODUCTION 
Irritable bowel syndrome can present in up to 15% of the global population, and is one of the 
most common gastrointestinal disorders worldwide affecting twice as many women as men, and 
is associated with poor economic status and healthcare costs in the billions of dollars every 
year
1,2
. Patients afflicted with IBS will present predominantly with one of two major subsets: 
IBS-C which is constipation predominant, or IBS-D which is diarrhea predominant. Regardless 
of the subset diagnosis, IBS is associated with several potential life disrupting symptoms 
including abdominal pain and/or discomfort, altered bowel movements, bowel distension and 
flatulence. In addition, external manifestations such as fibromyalgia, chronic pelvic pain and 
chronic fatigue syndrome are seen in this patient population.
1
 A frustrating aspect for IBS 
patients is the diagnosis process. While the Rome III criteria
2 
is set to diagnose IBS it is not 
typically used clinically and IBS remains to be a diagnosis of exclusion. Patients are often 
subjected to multiple invasive and non-invasive gastrointestinal tests searching for occult blood 
and parasites or bacteria such as C. difficile, only to have inconclusive results.
1
 The Rome III is 
the most widely used and the most clinically relevant diagnostic criteria in clinical trials 
assessing IBS. These criteria
2
 are provided in the following section. 
The Rome III Criteria for Diagnosing Irritable Bowel Syndrome
2 
IBS is a chronic disorder characterized by abdominal pain or discomfort associated with 
disordered defecation. Symptoms should have developed at least 6 months before the diagnosis 
can be made. 
Diagnostic criteria must include both of the following: 
1. Abdominal discomfort or pain should be present at least 3 days per month for 3 months 
and should be associated with 2 or more of the following at least 25% of the time: 
a) Improvement with defecation 
b) Onset associated with a change in frequency of stool 
c) Onset associated with a change in form (appearance) of stool 
2. No evidence of an inflammatory, anatomic, metabolic or neoplastic process that explains 
the patient’s symptoms 
Pathophysiology of IBS 
The pathophysiology of IBS is complex and involves many potential unknown mechanisms
3
. 
These mechanisms may consist of: food sensitivities (impaired carbohydrate absorption, gluten 
sensitivity and food allergies), visceral hypersensitivity caused by bloating or distension (which 
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send messages to the brain via afferent neural pathways indicating a feeling of pain), altered gut 
flora (leading to irregularity and pain), disordered intestinal motility, and psychological stressors 
(causing days regulation in the gut-brain axis). Neurotransmitters in the CNS and gastrointestinal 
tract, including serotonin and melatonin (a close derivative of serotonin), influence motility, 





Since the etiology of IBS is not fully understood and it is highly patient variable, treatment goals 
are usually based on symptom management. Traditional strategies include dietary manipulation, 
fiber intake, probiotics, antispasmodics, antidiarrheals, anitdepressants, and serotonergic agents.
1
 
Dietary manipulation.  
Dietary manipulation is usually the first recommendation. Patients often report certain foods they 
can and cannot eat, and are encouraged to avoid the foods the might cause upset. Gluten-free and 
low FODMAP (fermentable, oligosaccharides, disaccharides, monosaccharides and polyols) 
diets show promise,
7-9
 but are patient specific and difficult to manage.  
Fiber 
Though increased dietary fiber intake seems like a logical treatment, insoluble fiber has shown to 
lead to greater discomfort and soluble fibers such as psyllium, do not alleviate symptoms in 
every patient.
10
 However fiber has a role in alleviating symptoms in IBS-C. 
Probiotics 
Probiotics have been suggested and studied extensively in IBS, but results have been 
inconclusive and inconsistent.
11-47
 No particular strain can be recommended.  
Antispasmodics 




 can provide temporary relief to 
patients with IBS-D, but not without anticholinergic side effects such as dry mouth, dizziness 
and blurred vision.  
Antidiarrheals 
Although loperamide may seem a logical choice in IBS-D, in clinical studies it has not been 




Depression and anxiety (psychological factors) have been observed as being quite frequent 
comorbidities in IBS, therefore antidepressants have been shown to have benefits in this disease. 
Both tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs)have 
been used in several randomized controlled trials
48,54-69
 and have been shown to provide relief 
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and reduce pain in IBS, both with a number needed to treat of 4.
1
However, common adverse 
events such as dry mouth and drowsiness limit the use of TCAs. 
Serotonergic agents 
There are different types of serotonin (5-HT) receptors in the gut, two of which have targeted 
therapies in the treatment of IBS symptoms. Visceral pain and intestinal transit are targeted by 5-
HT3 antagonism using alosetron (Lotronex™). While alosetron has shown efficacy, it has also 
shown instances of severe constipation and ischemic colitis.
70 
This adverse effect has caused the 
FDA to restrict its use to women suffering with severe diarrhea-predominant IBS. 
Gastrointestinal transit and secretion are targeted by 5-HT4 agonists such as tegaserod 
(Zelnorm™). Unfortunately, while it has been proven to be effective in women with IBS-C,71 it 
was withdrawn from the market in 2007 due to possible cardiovascular adverse events
72
. No new 
agents in this class have efficacy or safety data available.  
Prosecretory agents 
Linaclotide (Linzess™) and lubiprostone (Amitiza™) have shown efficacy in IBS-C as 
prosecratory agents.
73-78
 Linaclotide results in an increase in chloride and bicarbonate, which 
draws sodium and water into the intestinal lumen. Lubiprostone is similar but results in chloride 
and water being drawn into the lumen decreasing transit time. The most commonly reported 
adverse event with each agent is diarrhea.  
MELATONIN 
General Information, Traditional and Alternative Uses 
Melatonin is a hormone known mostly for its release by the pineal gland located in the center of 
the brain. Melatonin is released at high concentrations during darker times of the day (eg. night), 
and is secreted to a much lesser extent when there is light. Its primary function involves 
maintaining the body’s circadian rhythm, or the 24-hour clock that keeps our sleep cycle stable 
and allows us to fall asleep and wake up at the appropriate time, as well as, adjusts to seasonal 
changes in light. Melatonin has been successfully used in the treatment of sleep disorders such as 
insomnia.
5,79 
In addition, melatonin has also been utilized in several other areas such as 
contraceptive use, fibromyalgia, certain types of cancer, and irritable bowel syndrome.
80
 
The Role of Melatonin in Irritable Bowel Syndrome 
Research shows that melatonin is also secreted in the gastrointestinal tract and has strong 
antioxidant properties, anti-inflammatory properties and is involved with intestinal motility 
regulation.
81-84
 All these methods contribute to the possibility of melatonin to induce symptom 
relief in patients with IBS. Melatonin has been shown to inhibit smooth muscle motility possibly 
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by stimulating certain receptors in the GI tract, as well as regulating calcium activated potassium 
channels in cells and blocking nicotinic receptors.
5-6 
Melatonin also may be involved in visceral 
sensation of the gut.
8 
While the exact mechanism is unknown, studies do show symptom relief in 
patients with IBS who take melatonin. 
5, 6, 79, 86 
SCIENTIFIC DATA 
A search was conducted using PubMed (keywords: melatonin and irritable bowel syndrome, no 
limits) and resulted in five small,
5,6,79,85,86
 double-blind, placebo-controlled trials (four of which 
were randomized) utilizing melatonin in irritable bowel syndrome. Four of the five studies tested 
symptom improvement; whereas, one study tested colonic transit time changes induced by the 
use of melatonin. Of these four studies, all showed a significant improvement in IBS symptoms. 
The study that focused on colonic transit time noticed an increase in colonic transit time with 
those who used melatonin. Each of the five studies was limited by small sample size, and 4 of the 
studies did not differentiate which IBS subtypes (IBS-C or IBS-D) benefited the most from the 
use of melatonin. These studies have been summarized in the next sections. A randomized, 
double-blinded, placebo-controlled study was conducted by Song et al
6 
in forty IBS patients aged 
20-64 years. Of the forty patients, 24 were female (8 male and 12 female in each study group) 
and patients with IBS-C as opposed to IBS-D was similar in both groups. Patients completed 
several questionnaires before the first administration of medication (or placebo) and immediately 
after two weeks of either placebo or study drug treatment. The drug regimen was either 
melatonin 3 mg or placebo at bedtime for two weeks. All forty patients completed the study, and 
no adverse events were reported. Results have been summarized in table 1.  
Table 1. Irritable Bowel Syndrome Symptom Scores Before and After Two Weeks of 
Treatment 
Parameter Baseline score Decrease in score after 2 weeks of 
treatment 
Melatonin 3mg Placebo Melatonin 3 mg Placebo p-value* 
Abdominal pain 4.05 3.85 2.35 0.70 <0.001 
Abdominal distension 4.00 3.15 1.05 0.15 NS 
Frequency of defecation 3.25 3.15 1.85 0.85 NS 
Stool type 6.15 6.25 0.65 0.55 NS 
Abnormal sensation of 
defecation 
7.10 7.70 1.30 1.35 NS 
Quality of life 5.80 5.45 1.25 0.95 NS 
Total score
# 
30.35 29.55 7.30 3.95 NS 
*Significance of the comparison between the melatonin and placebo groups  
#
A score of > 20 suggests the presence of significant bowel dysfunction 
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This was the first study to address the role of melatonin in IBS. The results showed a decrease in 
IBS symptoms evaluation score questionnaire (IBSSESQ) scores from baseline to two weeks 
which was not deemed as significant compared to placebo.  However, as seen in Table 1, the 
decrease of abdominal pain in patients was found significant. Lu et al
79
 conducted a randomized, 
double-blinded, placebo-controlled, 16-week crossover study that examined improvement in IBS 
symptoms (using IBSSESQ scores) in 17 women aged 24-66. Patients received either melatonin 
3 mg or placebo at bedtime for 8 weeks, followed by a washout period for 4 weeks, melatonin 
and placebo in reverse order for an additional 8 weeks. Patients were required to suffer from IBS 
symptoms at the time of the study, and have a score of at least moderate severity. Adverse events 
were not noted while on the study drug. Results are shown in Table 2. 
Table 2: Irritable Bowel Syndrome Symptom Scores at Baseline and After Study 
Completion 






Mean baseline IBS symptom scores (s.d.)* 11.1 (4.2) 11.8 (3.4) 1.0 
Change in mean IBS symptom scores (s.d.) 3.9 (2.6) 1.3 (4.0) 0.037 
Change in mean abdominal pain scores (s.d.) 1.17 (1.2) 0.47 (1.6) 0.045 
Change in mean abdominal distension scores (s.d.) 0.62 (0.6) 0.12 (0.7) 0.019 
Change in mean abnormal sensation of defecation scores (s.d.) 1.15 (1.1) 0.24 (1.3) 0.04 
Change in mean stool consistency scores (s.d.) 0.45 (0.7) 0.41 (0.9) 0.9 
Change in mean frequency of defecation scores (s.d.) -0.7 (1.1) -0.9 (1.4) 0.7 
* s.d. stands for standard deviation  
While this study included patients with less severe disease than the patients who were enrolled in 
the previous study,
6
 there was still significant improvement in areas including overall 
improvement in symptoms, improvement in abdominal pain scores, improvement in abdominal 
distension scores, and improvement in abnormal sensation of defecation scores. In a third study, 
Sahaet al
85
 conducted a randomized, double-blinded, placebo-controlled trial in 18 patients aged 
18-65 over the course of 8 weeks. Nine patients were given melatonin 3 mg at bedtime, and nine 
patients were given an identical placebo. Adverse events were reported in each group: one 
patient from the melatonin group and one patient from the placebo group reported drowsiness. 
An unspecified IBS score was used to assess severity of symptoms in the 18 patients, and results 
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Table 3: IBS Scores at Baseline and After Eight Weeks of Treatment 
Parameter Melatonin (n=9) Placebo (n=9) 
Baseline After p-Value Baseline After p-Value 




60 (10-100) 60 (0-100) >0.05 




70 (5-100) 80 (0-100) >0.05 
Bloating 70 (10-100) 30 (10-50) <0.001* 70 (20-100) 60 (10-100) >0.05 
Bowel habit 
dissatisfaction 
60 (10-85) 30 (0-50) <0.01* 50 (10-90) 45 (0-100) >0.05 



















overall IBS score 
45% (39 to 71) 16.7 (-16 to 47.3) 
*When compared with baseline values 
#
When compared between groups 
☨Scoring system used not specified 
The results of this study showed clinically significant improvement in the patients treated with 
melatonin as compared with placebo. While the results seem promising, this study had a very 
small sample size, and the scoring system used was not revealed. Also, it does not appear to be 
the same scoring system used in the previous two studies. The previous studies used an adapted 
model of the IBS symptoms evaluation score questionnaire (IBSSESQ) which at most could 
have had a maximum point value of 70.
87 
This study uses a scoring system which exceeds a score 
of 400. The range in scores, as compared to the reported median is also something to note, 
especially with such a small sample size as this could skew the results. Lu et al
86
conducted a 
randomized, double-blinded, placebo-controlled 16-week crossover study with a 4-week washout 
period to evaluate the colonic transit time (CTT) in 17 individuals taking either melatonin 3 mg 
or placebo once daily as compared with 17 matched healthy controls. CTT measurements 
included the radio-opaque, blue dye, and Bristol stool form score methods. The aim of the study 
was to see if melatonin would affect the CTT in individuals with IBS. Results showed that in 
normal healthy patients, melatonin increased the CTT (mean + SD: from 27.4 +10.5 to 37.4 
+23.8 hours; p=0.04). However, IBS patients did not show a significant change in CTT after 
treatment. Regardless, investigators of this study concludes that melatonin may still be beneficial 
in IBS patients despite their results due to the other studies that have been conducted.
6, 79, 8
. 
Finally, Chojnacki et al
5
 conducted a double-blinded, placebo-controlled but not randomized 
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study. This was the largest of the five studies, with 80 participants: 40 participants with IBS-D, 
and 40 with IBS-C. All 80 participants were post-menopausal women aged 48-65. Patients were 
chosen based on the premise that melatonin secretion in the gastrointestinal tract decreases with 
age, particularly in post-menopausal women. Each group, the 40 women with IBS-D and the 40 
women with IBS-C were stratified into two arms: melatonin 3mg in the morning upon 
awakening and 5mg at bedtime, or placebo in a double-blinded fashion. A ten-point scale was 
used to assess clinical improvement by distinguishing disease severity: mild stage (1-4 points), 
moderate stage (5-7 points) and severe stage (8-10 points). Patients were to keep an observation 
diary in which they noted intensification of visceral pain, abdominal bloating, and constipation 
or diarrhea. The results have been summarized in Table 4. 
Table 4: Differences in Symptom Scores from Baseline to Month 6 
Parameter IBS-C Patients (n=40) IBS-D Patients (n-40) 
Placebo Melatonin Placebo Melatonin 
Symptoms score at baseline 7.05 7.40 7.60 7.75 
Symptoms score at month 6 5.75 3.55 6.55 6.10 
Results showed the patients who benefited the most from melatonin were the patients with IBS-
C, who had clinically and statistically significant decreases in symptoms compared to placebo. 
Patients with IBS-D did not show significant improvement. Melatonin was well tolerated in both 
groups with only two patients with complaints of fatigue in the first week of treatment with 
melatonin. This was the first study to distinguish between the subtypes of IBS patients and utilize 




 support the use of melatonin in IBS, their small sample size 
and lack of differentiation in type of IBS limits its clinical use.  Studies specific to IBS-C and 
IBS-D can help to optimize therapy.  Doses of 3 to 8mg have been proven to be effective in 
patients with IBS-C.
5,6, 79, 85
 Doses of 3mg of melatonin prolonged colonic transit time, which 
could prove beneficial in patients with IBS-D.
86 
Available literature shows a positive correlation 
between the use of melatonin and symptom relief in IBS symptoms, thereby identifying it as a 
promising future treatment. 
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